BRAF and metastatic melanoma: As exemplified by trials for BRAF V600E metastatic melanoma, treatment with dabrafenib monotherapy versus the combination of dabrafenib and trametinib in BRAF V600E mutated melanoma [27] can significantly improve overall survival without increasing overall toxicities.